ASCO 2019 End-of-study Survival Analysis from the Cleopatra Study Shows Significant Benefit for Pertuzumab Plus Trastuzumab/Docetaxel in HER2-Positive Metastatic Breast Cancer

13,921 views
June 26, 2019
7 Comments
Login to view comments. Click here to Login